AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06798337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reward based physiotherapy group
Description: Subjects in the reward group performed balance and coordination exercises three times a week, with the inclusion of rewards. At the end of each exercise session, participants engaged in game-like interactive tasks using virtual reality (VR) glasses. Exercise sessions were conducted at the same time for each subject, with a permissible variation of ±1 hour.
Study NCT05665244 — intervention group
Intervention type: PROCEDURE
Intervention: Laryngeal cryotherapy
Description: Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.
Study NCT05665244 — intervention group
Intervention type: DEVICE
Intervention: Cryoprobe
Description: Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
Study NCT04783220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive structured parent intervention
Description: 1. Educational sessions and coaching on infants' behavior cues~2. Skills on motor stimulation~3. Written instructions for play and stimulation activities at discharge~4. Multidisciplinary follow-up~5. Developmental tracking and advice via a mobile app
Study NCT05778071 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: eneboparatide
Description: Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens
Study NCT05778071 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
Study NCT05807256 — intervention group
Intervention type: OTHER
Intervention: collection and analysis of treatments and procedures already performed by normal clinical practice
Description: The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
Study NCT05016817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT05970003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Copenhagen exercises
Description: Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening.
Study NCT05970003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Holmich exercises
Description: The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening.
Study NCT05877872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced-target resection
Description: Patients receive surgery according to pSTV-post-IC.
Study NCT05877872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-target resection
Description: Patients receive surgery according to pSTV-pre-IC.
Study NCT05877872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant immunotherapy
Description: Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Study NCT05877872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy
Description: Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Study NCT05964426 — intervention group
Intervention type: OTHER
Intervention: Turkey Health Literacy Scale (TSOY-32)
Description: A survey will be conducted.
Study NCT06062641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-GDP
Description: Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
Study NCT04955951 — intervention group
Intervention type: DEVICE
Intervention: polarized light
Description: A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
Study NCT04955951 — intervention group
Intervention type: DRUG
Intervention: Topical corticosteroid ointment
Description: corticosteroid 1 %.
Study NCT05179265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human serum albumin
Description: 10 g/bottle (20%, 50 mL)
Study NCT05179265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human serum albumin
Description: 10 g/bottle (20%, 50 mL)
Study NCT06509022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PEPTEST test
Description: Quantitative determination of gastric salivary amylase。
Study NCT06169943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth social support program
Description: This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
Study NCT06169943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The same mobile app as the intervention group but with limited function.
Study NCT06302426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INI-4001
Description: INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
Study NCT06302426 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.
Study NCT06302426 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
Study NCT06302426 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
Study NCT06302426 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
Study NCT06302426 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
Study NCT05633420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyramax
Description: Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)
Study NCT04770012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
Study NCT04770012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
Study NCT04770012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
Study NCT06799559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-6mg QLM1016
Description: 3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks
Study NCT06799559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-20 mg Aripiprazole oral solution film
Description: 10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.
Study NCT06799351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Description: Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
Study NCT06799351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (placebo)
Description: Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Study NCT06799377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Restricted Activity Reccomendations
Description: Patients in this respective group will be given restricted activity recommendations over the casting period. They will be told Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the restricted activity group. We ask that you limit sprinting, jumping, and organized sports during the time of cast immobilization. As a rule of thumb, we recommend feet on the floor activities while playing and avoiding playgrounds and gym class if possible. While it is not realistic to restrict a young child entirely, do your best to avoid strenuous or intense exercise until cleared by your physician or nurse practitioner
Study NCT06799377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full Activity/Limited Activity Reccomendations
Description: Patients in this respective group will be allowed to engage in most activities. They will be read Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the activity as tolerated group. Your child may participate in all desired activities except contact sports. Your child does not need to increase his/her activity level but should participate in activities as they feel comfortable doing so. Sprinting, jumping, and organized sports are acceptable as long as your child is not experiencing pain. Your child may use playgrounds and participate in gym class as desired. Do your best to avoid restricting your child from activities unless they are experiencing pain or you have concerns about their safety.
Study NCT06798753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion Balloon Catheter
Description: The occlusion balloon catheter (OBC) is a type of ureteral catheter equipped with a small inflatable balloon at its tip. When inflated, the balloon can help prevent the migration of stone fragments.
Study NCT06798753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5FR Ureteral Catheter
Description: The 5FR ureteral catheter (5FR-UC) is an open-ended small-caliber tube inserted at the beginning of PCNL to facilitate visualization of the collecting system using fluoroscopy and assist with renal access.
Study NCT06545942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOMA-313
Description: MOMA-313 administered orally
Study NCT06545942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib administered orally
Study NCT06563128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clearfil Majesty Posterior
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
Study NCT06563128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnichroma Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
Study NCT06563128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zen Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
Study NCT06563128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vittra Aps Unique Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
Study NCT06563128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charisma Diamond Universal Group
Description: After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
Study NCT06461897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablet or Oral Solution
Study NCT06259032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical alignment
Description: Goal alignment in TKA with mechanical alignment, resection bone in perpendicular to mechanical axis of femur and tibia.
Study NCT06259032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional alignment
Description: Goal alignment in TKA with functional alignment, resection of bone base on native joint line obliquity.
Study NCT06302426 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
Study NCT06461897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous Injection
Study NCT06071221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthy educational program + peer coaching
Description: The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
Study NCT06071221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Healthy educational program
Description: Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
Study NCT05593107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]N188
Description: 68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Study NCT05904080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05904080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05904080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05904080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05904080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05904080 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT05904080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT05904080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05904080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05904080 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT05904080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05304767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Study NCT06566820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aroxybutynin and Atomoxetine
Description: Fixed Dose Combination
Study NCT06153251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986453
Description: Specified dose on specified days
Study NCT06153251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT06153251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT05896254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAR001
Description: Subcutaneous injection
Study NCT05896254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT05695339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma (aiming at its proximal end) and dorsal adjacent tissue including the skin dorsally to the neuroma. This is to prevent pain caused by any microscopic spills of RTX during the. A second local anesthetic depot will be placed 1-2 cm proximally to the injection site around the affected branch of the plantar nerve to prevent pain caused by passive current transmission by axonal RTX excitation. Following the course of the affected nerve branch and ultra-sound visualization of the injection site, 0.5-2 ml bupivacaine 0.5% will be injected perineurally. Once the site has sufficient nerve block, the required RTX dose in a solution of 0.25 ml will be injected directly proximal to the Morton s neuroma under ultra-sound visualization.
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO